Company: MYSZ
Filing Date: 2025-03-10
Form Type: 8-K
Source: 0001493152-25-009696
Chunk: 0

Company: My Size, Inc.
Filing Date: 2025-03-10
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item      Departure                                                                                                                                 

As
previously disclosed, Or Kles, the Chief Financial Officer of My Size, Inc. (the “ Company”) resigned effective March 31,2025. On March 6, 2025, the Company appointed
Oren Elmaliah as the Company’s Chief Financial Officer, effective April 1, 2025 to replace Mr. Kles. As a then member of the board
of directors of the Company, Mr. Elmaliah stepped down as a member of the board and all committees of the board of directors of the Company.
Mr. Elmaliah’s biography is included in the Company’s definitive proxy statement filed with the Securities and Exchange Commission
on November 4, 2024 and is incorporated by reference herein.

In
connection with Mr. Elmaliah’s appointment, the Company entered into an agreement with Accounting Team Ltd., an entity 100% owned
by Mr. Elmaliah pursuant to which it was engaged to provide bookkeeping, controller and CFO services (the “ Services”), effective
from March 1, 2025. Under the agreement, the Company agreed to pay Accounting Team a monthly fee of NIS 40,000 (approx $11,000) for the
provision of the Services.

Additionally,
on March 6, 2025, the Company’s board of directors appointed Roy Golan as a Class I director to replace Mr. Elmaliah, effective
immediately. Mr. Golan’s initial term expires at the 2025 annual meeting of stockholders. Mr. Golan was additionally appointed
to the Audit Committee as chair, the Compensation Committee, and Nominating and Corporate Governance Committee.

Mr.
Golan acts as a financial advisor since July 2024 and currently
serves as a director of Neurosense Therapeutics Ltd. (NASDAQ: NRSN), a Nasdaq listed company developing treatments for severe neurodegenerative
diseases, since July 2024. Mr. Golan previously served as the Chief Financial Officer of Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a
clinical-stage oncology company, from its merger with BioSight Ltd., a private pharmaceutical company developing innovative therapeutics
for hematological malignancies and disorders, in October 2023 until June 2024. From 2019 to June
2024, Mr. Golan served as Executive VP and Chief
Financial Officer of BioSight Ltd. From